In line with these results, Porta et al. showed that, in a large percentage of advanced RCC patients treated with sunitinib, disease progression is preceded by a significant increase in IL-6 and also of other two proangiogenic cytokines (bFGF and HGF) [138]. This evidence concerns the gene HGF and renal cell carcinoma.